Physiomics Regulatory News (PYC)

Physiomics plc

(the "Company" or "Physiomics")

Share Price Movement

Following the recent movement in its share price today, the Company notes that ValiRx plc has today announced some positive results relating to their VAL 201 compound.

As announced on 13 September 2011, Physiomics has a revenue sharing deal in place with ValiRx in respect of VAL 201.

Today's announcement from ValiRx sets out the results from an independent pre-clinical study into VAL201 and confirms that ValiRx has started the regulatory filing process towards a phase I clinical trial application for VAL201 with the relevant regulatory bodies in the UK and Europe.

Enquiries:

Physiomics plc

Dr Mark Chadwick, CEO

+44 (0)1865 784 980

WH Ireland Limited (broker/nomad)

Katy Mitchell

+44 (0) 161 832 2174

Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029